Figure 10
The knockdown of Nrf2 enhanced oxaliplatin-induced growth inhibition of HCT116 xenografts tumor in vivo. (A–C) The knockdown of Nrf2 enhanced the growth inhibition of oxaliplatin, and the tumors were significantly decreased in size, volume, and weight. (D–F) By the IHC staining of tumor tissues, in the Nrf2 knockdown + oxaliplatin group, we found that the expression of Ki-67 was diminished. In contrast, the expression of cle-caspase3 was relatively low in the Nrf2 knockdown + oxaliplatin group. (G, H) The knockdown of Nrf2 increased oxaliplatin-associated ROS production. Data are shown as the mean ± SD, *p < 0.05; ***p < 0.001; ns (not significant).
